Table 3

Prevalence of potentially serious drug–drug interactions and regression analyses for risk of interaction

FC
(n=151 632)
FDC
(n=307 833)
Drug–drug interaction, n (%)20 206 (13.33)28 477 (9.25)
  ARB4905 (3.23)8706 (2.83)
  ACE inhibitor5114 (3.37)7623 (2.48)
  Beta blocker78 (0.05)43 (0.01)
  Calcium channel blocker12 775 (8.43)16 378 (5.32)